Xspray Pharma employs Charlotta Liljebris as Vice President Research & Development

Xspray Pharma has employed Charlotta Liljebris as head of research with the title Vice President R&D. She has more than 25 years’ experience from the Life Science-sector with a primary focus on business development and the commercial aspects of pharmaceutical developments. In addition, she has previously held several leading positions within research and development. She has most recently been responsible for commercialization processes through partner agreements and product positioning for products aimed at the American market at Orexo.

 

”Since last year’s capital infusion and positive study results we have greatly increased the pace of our development efforts. Charlotta Liljebris has an exceptionally well suited profile for strengthening the organisation in the continuing effort of developing our product candidates of already known substances to a commercial phase for the American market,” comments Per Andersson, CEO, Xspray Pharma.

Charlotta Liljebris will assume her position no later than May 1st 2018.

For additional information, please contact:

Per Andersson, CEO, Xspray Pharma AB (publ)
Mobile: +46 (0)706 88 23 48
E-mail: per.andersson@xspray.com

 

About Xspray Pharma

Xspray Pharma AB (publ) is a product development company with several product candidates under clinical development. Xspray uses its innovative RightSize-technology in order to develop improved and generic versions of already marketed cancer drugs, primarily protein kinase inhibitors (PKI), for treating cancer. The segment is the second largest within the oncology department and the drug prices are very high. Through its innovative technology, Xspray can enter the market as first competitor to the original drugs available today without the hindrance of secondary patents. Xspray’s goal is to ha three products ready for launch on the American market during the period 2020-2023, with a first product launched at the latest by 2021. The company has patents on production technology, equipment and the resulting products. The shares in Xspray Pharma (publ) are traded on Nasdaq First North Stockholm and Redeye is the Certified Adviser for the company.

 

Xspray Pharma AB (publ)

Gunnar Asplunds Allé 32

171 63 Solna

www.xspray.com